Polymyxin B1-d7 (TFA)

O=C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@@]1([H])[C@H](O)C)=O)CCN)=O)([H])CCN)=O)CC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])[C@H](NC([C@@H](NC([C@@](CCNC1=O)([H])NC([C@H](CCN)NC([C@H]([C@H](O)C)NC([C@H](CCN)NC(CCCC[C@@H](C)CC)=O)=O)=O)=O)=O)CCN)=O)CC2=CC=CC=C2.OC(C(F)(F)F)=O.[5]

[1]Kwa AL, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb;60 (2) :163-7.|[2]Berglund NA, et al. Interaction of the antimicrobial peptide polymyxin B1 with both membranes of E. coli: a molecular dynamics study. PLoS Comput Biol. 2015 Apr 17;11 (4) :e1004180.|[3]Tam VH, et al. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother. 2011 Sep;55 (9) :4490-1.|[4]Alonso MA, et al. Compounds affecting membranes that inhibit protein synthesis in yeast. Antimicrob Agents Chemother. 1979 Dec;16 (6) :750-6.|[5]Sivanesan S, et al. Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats. J Nat Prod. 2017 Jan 27;80 (1) :225-229.